Following an excellent presentation at the EAACI Digital Congress 2020, we caught up with Lavinia Davidescu (University of Oradea, Romania). We discussed the findings from the phase 3 study of masitinib in the treatment of patients with severe persistent asthma (NCT01449162) and what the future holds.
Questions
1. Could you tell us a little about masitinib and its mechanism of action? (0:04)
2. Could you give us an overview of Study AB07015 and its major efficacy and safety findings? (1:24)
3. What were the findings of the subgroup analysis in eosoniphilic asthma patients, and what are the implications of these findings? (04:29)
4. What future studies are planned? (11:26)
Speaker disclosure: Lavinia Davidescu is the coordinating investigator of masitinib study AB07015 in severe asthma uncontrolled with oral corticosteroids.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EAACI Digital Congress 2020.
